"Medroxyprogesterone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
(6 alpha)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione. A synthetic progestational hormone used in veterinary practice as an estrus regulator.
Descriptor ID |
D008525
|
MeSH Number(s) |
D04.210.500.745.745.654.829.395.700
|
Concept/Terms |
Medroxyprogesterone- Medroxyprogesterone
- Methylhydroxyprogesterone
- 17 alpha-Hydroxy-6 alpha-Methylprogesterone
- 17 alpha Hydroxy 6 alpha Methylprogesterone
|
Below are MeSH descriptors whose meaning is more general than "Medroxyprogesterone".
Below are MeSH descriptors whose meaning is more specific than "Medroxyprogesterone".
This graph shows the total number of publications written about "Medroxyprogesterone" by people in this website by year, and whether "Medroxyprogesterone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Medroxyprogesterone" by people in Profiles.
-
The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21; 142(12 Pt 1):953-62.
-
Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay. Gynecol Oncol. 1989 Jan; 32(1):55-9.
-
Cytochemical examinations of Ca, cytochrome oxidase and succinate dehydrogenase enzymes in endometrium carcinomatous tissue after high dose progestogen treatment. Acta Morphol Hung. 1988; 36(3-4):177-83.
-
Continuous, high-dose progestogen treatment of endometrial cancer. Gynecol Obstet Invest. 1987; 24(4):262-6.